Press Releases

European Medicines Agency Selects Aetion to Support Safety and Efficacy Research in Europe

Aetion has been selected by the European Medicines Agency to support the agency’s Quality, Efficacy, and Safety Studies on Medicines. Aetion is a health care analytics company, working to provide real-world evidence for regulators, manufacturers, and purchasers of medical treatments and technologies. The company was founded by Harvard Medical School faculty members and uses its Evidence Platform® to analyze data and produce honest scientific answers about value, safety, and efficacy. Aetion will perform pharmacoepidemiologic research for the European Medicines Agency and generate real-world-evidence to aid...

Biopharma Industry Leaders Ian Read and Clive Meanwell Join Saama Board of Directors

The Saama Board of Directors recently gained some highly respected leaders in Ian Read, former CEO and executive chairman of Pfizer, and Clive Meanwell, former CEO and founder of The Medicines Company. This news was revealed after a $430 million strategic investment in Saama by Carlyle and co-investors including McKesson Ventures, Amgen Ventures, Population Health Partners, Merck Global Health Innovation Fund, Northpond Ventures, Intermountain Ventures, and Pfizer Ventures. “It’s an honor to join Saama’s Board of Directors and the industry experts who comprise it,” Read said...

Survey Says Moms Want In-Person Care With a Side of Digital Health

Digital health company Xealth announced a recent survey examining new mothers and their expectations for digital health in comparison with the healthcare services they received. The survey was conducted among over 1,000 new or expectant mothers, with 57 percent of them showing a more favorable opinion of digital health since the beginning of the pandemic. The study also found that telehealth appointments have increased by 540 percent among respondents, although 83 percent still had in-person visits with their doctor. Price transparency matched least with patient expectations,...

Hims & Hers Unveils Mobile Platform For Their Over 500,000 Subscription Members

Hims & Hers announced plans to provide a further encompassing and personalized care experience with the launch of its mobile application. The app is expected to be available for the company’s more than 500,000 subscription members within the coming weeks. Hims & Hers Co-founder and CEO Andrew Dudum detailed the project, stating that the unveiling “marks one of the most important announcements in our company’s history as we continue toward our goal of fundamentally reshaping what it means to access and experience great modern healthcare.” Dudum...

Clinical Ink Acquires Digital Artefacts

Global clinical trial data and technology company Clinical Ink has announced its acquisition of Digital Artefacts, a digital technology company that specializes in data capture for complex cognitive, behavioral, and physiological research. “Data derived from Digital Artefacts can now increase the richness of our partners’ study data through the convergence of passive and active digital assessments,” said Clinical Ink CEO Ed Seguine. “Their wearables and sensors acumen provides instrumented data collection that complements our existing products and solutions.” The combination of the two companies provides other benefits...

Koneksa Broadens Multi-Year CNS Research Collaboration with Sanofi

Digital Biomarker company Koneksa announced an extension to its collaboration with Sanofi in central nervous system clinical trials. Sanofi is one of the world’s top biopharmaceutical companies, and Koneksa CEO Chris Benko expressed enthusiasm for the extension: “We’re proud that our long-term partnership has enabled Sanofi’s deployment of digital measures across multiple therapeutic areas and modalities.” He also noted continued collaboration with Sanofi will open an opportunity to study new treatment options for neurological diseases like multiple sclerosis. Specifically, Koneksa’s work with Safoni will benefit research...

FDA Selects Aetion Evidence Platform® to Advance Regulatory Science and Innovation

Aetion announced that it is expanding its relationship with the U.S. Food and Drug Administration to use real-world evidence to study COVID-19 interventions and advance regulatory science and innovation. The FDA and Aetion will use the Aetion Evidence Platform, validated software that enables efficient, transparent, and reliable RWE research, to develop a framework and system of studies for the rapid assessment of COVID-19 inpatient medical products. The project is designed to demonstrate how using a platform-based approach furthers regulatory learnings on the use of RWE to...

Carlyle and Leading Healthcare-Focused Venture Finds Announce Strategic Growth Investment of up to $430 Million in Saama

Saama Technologies announced that funds led by global investment firm Carlyle have made a strategic growth investment and will acquire a majority stake in the company. A broad co-investor group with several healthcare-focused venture funds including Amgen Ventures, Intermountain Ventures, Merck Global Health Innovation Fund, McKesson Ventures, Northpond Ventures, Pfizer Ventures, and Population Health Partners, will be investing alongside Carlyle. The partnership will allow Saama to accelerate its strategic initiatives including expanding its go-to-market capabilities and further investing in AI research and development. Saama’s intelligent Life Science...

Trinity Health Invests in Xealth to Accelerate Digital Health

Xealth has announced that Trinity Health, one of the nation’s largest Catholic healthcare systems, has invested in the company, bringing Xealth's total Series B funding to $25 million. This support demonstrates continued provider consensus in adopting digital health in a way that best engages both clinicians and patients. Digital therapeutics, mobile apps, and remote patient monitoring help fill a necessary role in extending care options for patients. Trinity Health is one of 15 healthcare systems that have funded Xealth; other investors include Advocate Aurora Enterprises, Banner...

Autolomous and Vineti form strategic partnership to deliver end to end supply chain management solutions for cell and gene therapy sector

Autolomous, a developer of critical manufacturing management systems for cell and gene therapies, and Vineti, a provider of digital enterprise platforms for cell and gene therapy supply chains, have announced a non-exclusive, collaborative partnership. The collaboration will integrate Autolomous’ critical manufacturing management systems with Vineti’s Personalized Therapy Management (PTM) platform. This will allow both parties to create a seamless end-to-end cell and gene therapy (CGT) delivery pathway, including critical inbound and outbound manufacturing value processes, which will result in an increase in the visibility and dynamic...